Calzada (CZD) AOD9604 Osteoarthritis and diseases related to muscle mass loss The company has received positive results from in-vitro tests conducted on its peptide compound, AOD9604. These studies were conducted in separate cartilage and muscle cell experiments using animal cell lines and were designed to explore AOD9604’s commercial potential.
http://www.pwc.com.au/industry/technology/assets/bioForum/BioForum-Ed39-Ch3-Apr12.pdf
Add to My Watchlist
What is My Watchlist?